纤维细胞生长因子-19,β-Klotho和受体之间的相互作用影响慢性病中的心血管风险
Laura González-Rodríguez1,2, Manuel Martí-Antonio3, Virginia Díaz-Acevedo1
1Department of Medical and Surgical Therapeutics, Medical School, Universidad de Extremadura, 06006 Badajoz, Spain.
Journal of clinical medicine
|February 13, 2026
概括
在FGF19/β-Klotho/FGFR轴中的生物标志物和遗传变异可以改善慢性病 (CKD) 患者的心血管风险预测. 整合这些因素可以提高风险分层,超越传统方法.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
背景情况:
- 慢性病 (CKD) 显著增加了心血管疾病 (CVE) 的风险.
- 传统的生物标志物往往低估了CKD患者心血管风险的增加.
研究的目的:
- 调查循环FGF19/β-Klotho/FGFR轴水平的作用以及CKD患者心血管风险分层中的遗传变异.
- 评估这些因素是否有助于在这个人群中预测心血管事件.
主要方法:
- 在579名CKD患者的血FGF19和β-Klotho度量化.
- 分析了FGF19,KLB,FGFR1和FGFR4基因中的64种遗传变异.
- 利用集群分析来确定生物标志物概况,并评估它们与无心血管事件存活率的关联.
主要成果:
- 确定了三种不同的生物标志物概况;一个具有低/中等FGF19和高β-Klotho的生物标志物显示了显著减少的CV无事件存活率.
- 这一特定的生物标志物集群独立地与更高的心血管风险相关 (HR = 2.97).
- 特定的遗传变异 (FGFR1 rs2288696,KLB rs2687971) 和一个综合风险模型 (C指数=0.80) 证明了预测价值.
结论:
- 循环的FGF19-Klotho生物标志物和遗传信息可以提高CKD的心血管风险预测.
- FGF19/β-Klotho生物标志物集群的预测重要性与已确定的风险因素相当.
- 整合这些新型标志物可能会导致对高风险CKD患者进行改善的临床管理和有针对性的干预措施.
相关概念视频
01:25Chronic Kidney Disease I: Introduction
768
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
768
01:24Chronic Kidney Disease II: Clinical Manifestations
688
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
688
01:28Chronic Kidney Disease III: Interprofessional Care
485
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
485
01:18Chronic Kidney Disease IV: Nursing Management
416
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
416
01:26Factors Affecting the Risk of Infection
13.9K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
13.9K
01:24Drug Toxicity: Risk factors
2
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
2